Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations

Authors: Piha-Paul, S.A. ^{1, ∗}, Tseng, C. ¹, Tran, H.T. ², Naing, A. ¹, Dumbrava, E.E. ¹, Karp, D.D. ¹, Rodon, J. ^{1, 3}, Yap, T.A. ^{1, 3, 4}, Raghav, K.P. ⁵, Damodaran, S. ⁶, Le, X. ², Soliman, P.T. ⁷, Lim, J. ⁸, Meric-Bernstam, F. ^{1, 3, 9}

Source: In ESMO Open February 2025 10(2)

PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

Authors: Yap, T.A., Choudhury, A.D., Hamilton, E., Rosen, L.S., Stratton, K.L., Gordon, M.S., Schaer, D., Liu, L., Zhang, L., Mittapalli, R.K., Zhong, W., Soman, N., Tolcher, A.W.

Source: In ESMO Open September 2024 9(9)

A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors

Authors: Gouda, M.A., Shunyakova, J., Naing, A., Dumbrava, E., Hong, D.S., Yuan, Y., Yang, P., Myers, A., Liang, Y., Peng, J., Karp, D., Tsimberidou, A.M., Rodon, J., Yap, T.A., Piha-Paul, S.A., Meric-Bernstam, F., Fu, S.

Source: In ESMO Open June 2024 9(6)

HER2-low expression in patients with advanced or metastatic solid tumors

Authors: Uzunparmak, B., Haymaker, C., Raso, G., Masciari, S., Wang, L., Lin, H., Gorur, A., Kirby, B., Cimo, A.-M., Kennon, A., Ding, Q., Urschel, G., Yuan, Y., Feng, G., Rizvi, Y., Hussain, A., Zhu, C., Kim, P., Abbadessa, G., Subbiah, V., Yap, T.A., Rodon, J., Piha-Paul, S.A., Meric-Bernstam, F., Dumbrava, E.E.

Source: In Annals of Oncology November 2023 34(11):1035-1046

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Authors: Araujo, D., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., de Bono, J., Drilon, A., Garralda, E., Ivy, P., Kholmanskikh, O., Melero, I., Pentheroudakis, G., Petrie, J., Plummer, R., Ponce, S., Postel-Vinay, S., Siu, L., Spreafico, A., Stathis, A., Steeghs, N., Yap, C., Yap, T.A., Ratain, M., Seymour, L.

Source: In Annals of Oncology January 2023 34(1):48-60

Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality

Authors: Maddalena, G., Zeineddine, F.A., Rivero-Hinojosa, S., Aushev, V.N., Chowdhury, S., Zeineddine, M.A., Yousef, A.M., Yap, T.A., EINaggar, A.C., Liu, M.C., White, M., Overman, M.J., Kopetz, S., Shen, J.P.

Source: In Annals of Oncology July 2024 35(7):678-680

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer

Authors: Weller, A., O'Brien, M.E.R., Ahmed, M., Popat, S., Bhosle, J., McDonald, F., Yap, T.A., Du, Y., Vlahos, I., deSouza, N.M.

Source: In European Journal of Cancer May 2016 59:65-78

19P Pharmacodynamic activity of [18F]-fluorthanatrace poly(ADP-ribose) polymerase (PARP) PET in BRCA1/2-mutated breast cancer patients receiving talazoparib

Authors: Lin, L., Wong, F., Yap, T.A., Litton, J.K.

Source: In ESMO Open February 2024 9 Supplement 1

201P Phase II study of taminadenant (A2AR antagonist) + spartalizumab (anti PD-1 antibody) in patients with triple-negative breast cancer (TNBC)

Authors: Jerusalem, G., De Braud, F.G.M., de Jonge, M.J.A., Grell, P., Gonçalves, A., Tan, T.J.Y., Greil, R., Yap, T.A., Lin, C-C., Kornbluth, K.A., Yang, X., Vong, C., Choudhury, S., Mataraza, J., Lee, L.H., Otero, J.A., Garralda, E.

Source: In Immuno-Oncology and Technology December 2022 16 Supplement 1

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

Authors: Arkenau, H.-T., Plummer, R., Molife, L.R., Olmos, D., Yap, T.A., Squires, M., Lewis, S., Lock, V., Yule, M., Lyons, J., Calvert, H., Judson, I. ^*

Source: In Annals of Oncology May 2012 23(5):1307-1313

193P Translational, PK, PD, and immunophenotyping analyses of tuvusertib + niraparib in a phase Ib open-label multicenter dose-escalation study in patients with advanced solid tumors (DDRiver Solid Tumors 301)

Authors: Tolcher, A.W., Yap, T.A., Plummer, R., Sommerhalder, D., Rodon, J., Lagonera, M., Bergmann, P., Perez, V. Sanchez, Wohlfeil, N., Wang, D., Mukker, J. Kaur, Sessa, G., Manginelli, A., de Bono, J.S.

Source: In Annals of Oncology September 2024 35 Supplement 2:S292-S293

190P A large scale proteogenomics atlas for precision oncology research

Authors: Yap, T.A., Pevzner, K., Simchi, N., Givton, O., Daitchman, D., Seger, E.

Source: In Annals of Oncology September 2024 35 Supplement 2:S291-S291

638P Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center

Authors: Tsimberidou, A.M., Fu, S., Hong, D.S., Piha-Paul, S.A., Naing, A., Rodon, J., Yap, T.A., Karp, D., Dumbrava, E.E., Heymach, J.V., Ajani, J.A., Cartwright, C., BecK, J., Andersen, C., Kahle, M., Vining, D., Ross, J.S., Chao, C., Berry, D.A., Meric-Bernstam, F.

Source: In Annals of Oncology September 2024 35 Supplement 2:S506-S507

619MO Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)

Authors: Carneiro, B.A., Rosen, E., Fontana, E., Lee, E.K., Mettu, N.B., Lheureux, S., Plummer, R., Silverman, I.M., Schonhoft, J.D., Yang, J., Gomez, G., Fei, K., Ulanet, D., Basciano, P.A., Yap, T.A., Hoejgaard, M.

Source: In Annals of Oncology September 2024 35 Supplement 2:S496-S496

618MO Phase Ib/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors

Authors: Yap, T.A., Yan, F., Sadeghi, S., Lin, T.T., Liu, F., Malky, L., Golmakani, M., Moreau, A., Neumann, H., Zhou, L., Juric, D., Sharma, M.R.

Source: In Annals of Oncology September 2024 35 Supplement 2:S495-S496

603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation

Authors: Guo, R., Dowlati, A., Dagogo-Jack, I., Vibert, J., Spira, A.I., Moreno Garcia, V., Punekar, S., Calvo, E., Sonpavde, G.P., Awad, M., Riess, J.W., Hernandez Guerrero, T.C., Herzberg, B., Italiano, A., Swalduz, A., Lorusso, P., Smit, E.F., Garon, E.B., Novotny, W., Yap, T.A.

Source: In Annals of Oncology September 2024 35 Supplement 2:S483-S484

413P Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors

Authors: Yap, T.A., Liu, F., Zhang, H., Roh, W., Giordano, A., Hamilton, E.P., Delioukina, M.L., Lira, M., Park, J., Basu, C., Sharma, M.R.

Source: In Annals of Oncology September 2024 35 Supplement 2:S392-S393

424P MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)

Authors: Ma, B.B.Y., Johnson, A., Mills Shaw, K.R., Loong, H.H.F., Mo, F., Lui, R.N., Wong, K.H., Zeng, Z., Holla, V., Kahle, M., Vu, T., Su, F., Kim, S-H., Conway, T., Wang, Q., Tao, W., Zhou, L., Rodon, J., Meric-Bernstam, F., Yap, T.A.

Source: In Annals of Oncology November 2023 34 Supplement 4:S1629-S1629

713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation

Authors: Dagogo-Jack, I., Dowlati, A., Guo, R., Awad, M.M., Swalduz, A., Calvo, E., Moreno Garcia, V., Adjei, A.A., Lorusso, P., Punekar, S., Leal, T.A., Yap, T.A., Italiano, A., Novotny, W., Tankersley, C., Rowe, S., Paris, G., Sun, W., Spira, A.I., Besse, B.

Source: In Annals of Oncology October 2023 34 Supplement 2:S493-S494

701P NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)

Authors: Yap, T.A., Piha-Paul, S.A., Karp, D., Dumbrava, E.E., Hong, D.S., Fu, S., Subbiah, V., Tsimberidou, A.M., Rodon, J., Rhudy, J., Valladolid, C., Yuan, Y., Jana, B., Spiliopoulou, P., Randall, L., Poklepovic, A., Sehgal, K., Shapiro, G.I., Said, R., Meric-Bernstam, F.

Source: In Annals of Oncology October 2023 34 Supplement 2:S487-S488